Latest Syndax News & Updates

See the latest news and media coverage for Syndax. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Syndax

Commercial-stage oncology company developing targeted cancer therapies

syndax.com
Headquarters
New York, United States
Company type
Public company
Number of employees
50–350

Last updated

Latest news about Syndax

In short: Syndax reported strong revenue growth and achieved several key regulatory milestones for its lead therapies Revuforj and Niktimvo throughout 2025.

Company announcements

  • Syndax

    Syndax reports Q1 2026 financial results

    Total revenue reaches $64.9 million, up 224% YoY. Revuforj nets $48.9 million, Niktimvo collaboration $15.9 million. Upcoming data in 2Q26 and 4Q26.

  • Syndax

    Syndax schedules Q1 2026 earnings call

    The conference call and webcast occur on April 30 at 4:30 p.m. ET. A replay follows.

  • Syndax

    Syndax reports Q4 and full-year 2025 financial results

    Total revenue reaches $68.7M in Q4 and $172.4M for the year. Revuforj nets $44.2M in Q4, Niktimvo $56.0M. Phase 2 IPF trial enrollment completed; topline data due Q4 2026.

  • Syndax

    Syndax schedules conference call

    The call on February 26 at 4:30 p.m. ET discusses Q4 and full year 2025 financial results and business update. A replay follows.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Syndax

Track Syndax and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Syndax competitors & trending companies

Browse news for competitors to Syndax and other trending companies.